Gout Disease Treatment Market, by Drug Class (Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine, Urate-lowering Agents, and Monoclonal Antibody), by Route of Administration (Oral and Injectable), by Distribution Channel (Hospital

Gout Disease Treatment Market, by Drug Class (Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine, Urate-lowering Agents, and Monoclonal Antibody), by Route of Administration (Oral and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Gout is the chronic disease characterized by pain and inflammation in the joint. It is also known as gout arthritis, in which high level of uric acid in blood leads to formation of the needle-like crystals in the joints resulting into inflammation and pain. The conditions can be treated or prevented with use of the drugs such as nonsteroidal anti-inflammatory drugs, corticosteroids, colchicine, and urate-lowering agents. Moreover, monoclonal antibody is also used to treat gout for certain cases in which, nonsteroidal anti-inflammatory drugs, corticosteroids, colchicine, and urate lowering agents are unresponsive to the patient.
Market Dynamics
Increasing prevalence of gout disease is expected to increase demand of anti-gout drugs, which is expected to drive growth of the gout disease treatment market growth in forecast period. For instance, according to the National Center for Biotechnology Information (NCBI) (Rheumatology journal), the prevalence of gout in 2015 increased in South Korea compared to 2007 (earlier reported prevalence). In 2007, the prevalence of gout disease in South Korea was 3.49 (3.48-3.51) per 1,000 persons and in 2015, the prevalence of gout disease in South Korea was 7.58 (7.55-7.60) per 1,000 persons. Moreover, according to the data from the Australian Bureau of Statistics 2017–2021 (a National Health Survey), an estimated 187,000 people of Australia (0.8% of the Australia population) were diagnosed with gout disease in 2017.
Key features of the study:
This report provides in-depth analysis of the global gout disease treatment market, market size (US$ Mn), and compound annual growth rate (CAGR %) over the forecast period (2022-2028), considering 2021, as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrixes for this market
This study also provides key insights about market drivers, restraints, opportunities, new technology launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles leading players in the global gout disease treatment market based on the following parameters – company overview, financial performance, technology portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include AstraZeneca Plc, Takeda Pharmaceutical Company Limited, Novartis International AG, Teijin Pharma Limited, Simcere Pharmaceutical, JW Pharmaceutical Corporation, Horizon Therapeutics plc., Hikma Pharmaceuticals Plc, Ironwood Pharmaceuticals, Inc., CymaBay Therapeutics, Inc., and Zyla Life Sciences
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future technology launches, governmental initiatives, technological up-gradation, market expansions, and marketing tactics
The global gout disease treatment market report caters to various stakeholders in this market, including investors, technology manufacturers, distributors, and suppliers in the global ophthalmic viscoelastic devices industry, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
Global Gout Disease Treatment Market, By Drug Class:
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Corticosteroids
Colchicine
Urate-lowering Agents
Monoclonal Antibody
Global Gout Disease Treatment Market, By Route of Administration:
Oral
Injectable
Global Gout Disease Treatment Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Gout Disease Treatment Market, By Region:
North America
By Country:
U.S.
Canada
By Drug Class:
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Corticosteroids
Colchicine
Urate-lowering Agents
Monoclonal Antibody
By Route of Administration:
Oral
Injectable
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Drug Class:
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Corticosteroids
Colchicine
Urate-lowering Agents
Monoclonal Antibody
By Route of Administration:
Oral
Injectable
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Drug Class:
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Corticosteroids
Colchicine
Urate-lowering Agents
Monoclonal Antibody
By Route of Administration:
Oral
Injectable
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Drug Class:
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Corticosteroids
Colchicine
Urate-lowering Agents
Monoclonal Antibody
By Route of Administration:
Oral
Injectable
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Drug Class:
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Corticosteroids
Colchicine
Urate-lowering Agents
Monoclonal Antibody
By Route of Administration:
Oral
Injectable
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Drug Class:
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Corticosteroids
Colchicine
Urate-lowering Agents
Monoclonal Antibody
By Route of Administration:
Oral
Injectable
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
AstraZeneca Plc*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Takeda Pharmaceutical Company Limited
Novartis International AG
Teijin Pharma Limited
Simcere Pharmaceutical
JW Pharmaceutical Corporation
Horizon Therapeutics plc
Hikma Pharmaceuticals Plc.
Ironwood Pharmaceuticals, Inc.
CymaBay Therapeutics, Inc.
Zyla Life Sciences
“*” marked represents similar segmentation in other categories in the respective section